Document Detail

Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
MedLine Citation:
PMID:  18305064     Owner:  NLM     Status:  MEDLINE    
Hormone-ablative therapies for breast or prostate cancer can cause marked and rapid reductions in circulating estrogen or testosterone levels, resulting in significant effects on bone metabolism and cancer treatment-induced bone loss (CTIBL). Most patients with cancer are over the age of 65 and are already at risk for osteoporosis. Thus, accelerated bone loss from CTIBL is especially concerning in this population. Although there are currently no approved therapies for the treatment or prevention of CTIBL, oral bisphosphonates have been used in settings other than oncology to treat bone loss. New-generation i.v. bisphosphonates have demonstrated promising activity in preventing CTIBL in patients receiving hormonal therapy for breast or prostate cancer. In particular, zoledronic acid not only prevents CTIBL in both breast and prostate cancer patients but also increases bone mineral density above baseline. Such agents have the potential to delay or prevent CTIBL in patients receiving hormonal therapies.
Adam M Brufsky
Related Documents :
1954344 - Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
21469174 - Synthesis and cytotoxicity of bis-1,3,4-oxadiazoles and bis-pyrazoles derived from 1,4-...
18059174 - Biology of breast cancer bone metastasis.
1923174 - Reduced spinal bone mass in patients with uterine cervical cancer.
23847214 - Breast cancer, version 3.2013: featured updates to the nccn guidelines.
1511144 - A model for quality assessment in cervical cytology used as a screening test.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The oncologist     Volume:  13     ISSN:  1083-7159     ISO Abbreviation:  Oncologist     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-28     Completed Date:  2008-05-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  187-95     Citation Subset:  IM    
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Hormonal / administration & dosage,  adverse effects*
Aromatase Inhibitors / adverse effects
Bone Density Conservation Agents / therapeutic use
Bone Resorption / chemically induced,  physiopathology*,  prevention & control*
Breast Neoplasms / drug therapy*
Diphosphonates / therapeutic use
Imidazoles / therapeutic use
Osteoporosis / prevention & control
Prostatic Neoplasms / drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Aromatase Inhibitors; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choos...
Next Document:  Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue.